Repository logo
 

Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).

Simple item page
cam.issuedOnline2022-06-14
dc.contributor.authorHasan, Zeeshaan-Ul
dc.contributor.authorAhmed, Ikhlaaq
dc.contributor.authorMatin, Rubeta N
dc.contributor.authorHomer, Victoria
dc.contributor.authorLear, John T
dc.contributor.authorIsmail, Ferina
dc.contributor.authorWhitmarsh, Tristan
dc.contributor.authorGreen, Adele C
dc.contributor.authorThomson, Jason
dc.contributor.authorMilligan, Alan
dc.contributor.authorHogan, Sarah
dc.contributor.authorVan-de-Velde, Vanessa
dc.contributor.authorMitchell-Worsford, Liza
dc.contributor.authorKentley, Jonathan
dc.contributor.authorGaunt, Claire
dc.contributor.authorJefferson-Hulme, Yolande
dc.contributor.authorBowden, Sarah J
dc.contributor.authorGaunt, Piers
dc.contributor.authorWheatley, Keith
dc.contributor.authorProby, Charlotte M
dc.contributor.authorHarwood, Catherine A
dc.contributor.orcidHasan, Zeeshaan-Ul [0000-0002-3391-2730]
dc.contributor.orcidGreen, Adele C [0000-0002-2753-4841]
dc.contributor.orcidKentley, Jonathan [0000-0002-7109-6199]
dc.contributor.orcidProby, Charlotte M [0000-0002-3292-4836]
dc.date.accessioned2022-06-14T12:00:07Z
dc.date.available2022-06-14T12:00:07Z
dc.date.issued2022-09
dc.date.submitted2021-09-24
dc.date.updated2022-06-14T12:00:06Z
dc.description.abstractBACKGROUND: The risk of cutaneous squamous cell carcinoma (cSCC) is significantly increased in organ transplant recipients (OTRs). Clearance of actinic keratoses (AKs) is generally regarded as a surrogate biomarker for cSCC prevention. OTR-cSCC chemoprevention with topical AK treatments has not been investigated in randomized controlled trials (RCTs), although there is evidence that 5% 5-fluorouracil (5-FU) may be chemoprotective in immunocompetent patients. OBJECTIVES: To assess the feasibility, activity and evaluation outcomes relevant to the design of a future phase III RCT of topical cSCC chemoprevention in OTRs. METHODS: OTRs with 10 or more AKs in predefined areas were randomized 1 : 1 : 1 to topical 5-FU, 5% imiquimod (IMIQ) or sunscreen (sun-protective factor 30+) in a phase II, open-label RCT over 15 months. Feasibility outcomes included proportions of eligible OTRs randomized, completing treatment and willing to be re-treated. AK activity [AK clearance, new AK development, patient-centred outcomes (toxicity, health-related quality of life, HRQoL)] and evaluation methodology (clinical vs. photographic) were assessed. RESULTS: Forty OTRs with 903 AKs were randomized. All feasibility outcomes were met (56% of eligible OTRs were randomized; 89% completed treatment; 81% were willing to be re-treated). AK activity analyses found 5-FU and IMIQ were superior to sunscreen for AK clearance and prevention of new AKs. 5-FU was more effective than IMIQ in AK clearance and prevention in exploratory analyses. Although toxicity was greater with 5-FU, HRQoL outcomes were similar. CONCLUSIONS: Trials of topical AK treatments in OTRs for cSCC chemoprevention are feasible and AK activity results support further investigation of 5-FU-based treatments in future phase III trials. What is already known about this topic? Cutaneous squamous cell carcinoma (cSCC) is significantly more common in immunocompromised individuals including organ transplant recipients (OTRs) compared with immunocompetent populations. cSCC chemoprevention activity of sunscreen and 5-fluorouracil-based (5-FU) actinic keratosis (AK) treatments has been demonstrated in randomized controlled trials (RCTs) in immunocompetent populations but not in OTRs. AKs are cSCC precursors and their clearance and prevention are generally regarded as surrogate endpoint biomarkers for potential cSCC chemoprevention activity. What does this study add? SPOT (SCC Prevention in OTRs using Topical treatments) has confirmed that RCTs of OTR-cSCC chemoprevention with topical AK treatments are feasible. It also suggests that topical 5-FU may be superior to 5% imiquimod and sunscreen in AK clearance and prevention. Together with recent evidence from several RCTs in the general population, these data provide a compelling rationale for further studies of intervention with 5-FU-based topical chemoprevention approaches in OTR-cSCC prevention.
dc.identifier.doi10.17863/CAM.85481
dc.identifier.eissn1365-2133
dc.identifier.issn0007-0963
dc.identifier.otherbjd20974
dc.identifier.otherbjd-2021-2213.r1
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/338072
dc.languageen
dc.language.isoeng
dc.publisherOxford University Press (OUP)
dc.publisher.urlhttp://dx.doi.org/10.1111/bjd.20974
dc.subjectCarcinoma, Squamous Cell
dc.subjectFeasibility Studies
dc.subjectFluorouracil
dc.subjectHumans
dc.subjectImiquimod
dc.subjectKeratosis, Actinic
dc.subjectOrgan Transplantation
dc.subjectSunscreening Agents
dc.subjectTransplant Recipients
dc.subjectTreatment Outcome
dc.titleTopical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
dc.typeArticle
dcterms.dateAccepted2021-12-30
prism.publicationNameBr J Dermatol
pubs.funder-project-idResearch for Patient Benefit programme (PB‐PG‐0110‐21244)
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc/4.0/
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1111/bjd.20974

Files

Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
bjd.20974.pdf
Size:
1.21 MB
Format:
Adobe Portable Document Format
Description:
Published version
Licence
http://creativecommons.org/licenses/by-nc/4.0/
Download
No Thumbnail Available
Name:
bjd.20974.xml
Size:
13.9 KB
Format:
Extensible Markup Language
Description:
Bibliographic metadata
Licence
http://creativecommons.org/licenses/by-nc/4.0/
Download

Collections

Jisc Publications Router